Press Brief

Genetic targeting in sickle cell disease

PAUSE: perioperative management of AF patients receiving direct oral anticoagulants

Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant

Corinne Summers

Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL

Specific BCL2 mutation confers resistance to venetoclax in progressive CLL

MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM

Ibrutinib/rituximab is superior to FCR for younger CLL patients in the frontline setting

Update on ELIANA for CAR T-cell product tisagenlecleucel in ALL

Reducing chemotherapy in DLBCL: FLYER results

Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook

Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL

Significantly improving HRQL and neurocognition in high-risk sickle cell following familial ASCT

REACH: hydroxyurea for sickle cell anemia in sub-saharan Africa

Opioid use in sickle cell is not associated with in-hospital mortality in the US

Oladimeji Akinola Akinboro

Luspatercept reduces transfusion burden in MDS-related anemia: MEDALIST results

CD19 CAR T-cells plus ibrutinib in R/R CLL may improve response & decrease CRS

Jordan Gauthier

1
2
3
4
5
Next